184 related articles for article (PubMed ID: 37543185)
1. Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD.
Badrani JH; Cavagnero K; Eastman JJ; Kim AS; Strohm A; Yan C; Deconde A; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2023 Nov; 152(5):1330-1335.e1. PubMed ID: 37543185
[TBL] [Abstract][Full Text] [Related]
2. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
[TBL] [Abstract][Full Text] [Related]
3. Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Laidlaw TM; Buchheit KM; Cahill KN; Hacker J; Cho L; Cui J; Feng C; Chen CC; Le M; Israel E; Boyce JA
J Allergy Clin Immunol; 2023 Sep; 152(3):700-710.e3. PubMed ID: 37068712
[TBL] [Abstract][Full Text] [Related]
4. Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease.
Cavagnero KJ; Doherty TA
Ann Allergy Asthma Immunol; 2021 Feb; 126(2):135-142. PubMed ID: 32950684
[TBL] [Abstract][Full Text] [Related]
5. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
White AA; Doherty TA
Am J Rhinol Allergy; 2018 Jan; 32(1):7-11. PubMed ID: 29336282
[TBL] [Abstract][Full Text] [Related]
6. Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.
Jerschow E; Edin ML; Pelletier T; Abuzeid WM; Akbar NA; Gibber M; Fried M; Lih FB; Gruzdev A; Bradbury JA; Han W; Hudes G; Keskin T; Schuster VL; Spivack S; Zeldin DC; Rosenstreich D
J Allergy Clin Immunol Pract; 2017; 5(4):998-1007.e2. PubMed ID: 28159558
[TBL] [Abstract][Full Text] [Related]
7. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
Buchheit KM; Sohail A; Hacker J; Maurer R; Gakpo D; Bensko JC; Taliaferro F; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2022 Aug; 150(2):415-424. PubMed ID: 35460728
[TBL] [Abstract][Full Text] [Related]
8. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
[TBL] [Abstract][Full Text] [Related]
9. Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
Mastalerz L; Celejewska-Wójcik N; Wójcik K; Gielicz A; Januszek R; Cholewa A; Stręk P; Sanak M
Allergy; 2014 Nov; 69(11):1550-9. PubMed ID: 25123806
[TBL] [Abstract][Full Text] [Related]
10. Levels of eicosanoids in nasal secretions associated with nasal polyp severity in chronic rhinosinusitis.
Nordström A; Jangard M; Svedberg M; Ryott M; Kumlin M
Prostaglandins Leukot Essent Fatty Acids; 2022 Sep; 184():102474. PubMed ID: 35917595
[TBL] [Abstract][Full Text] [Related]
11. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease.
Machado-Carvalho L; Martín M; Torres R; Gabasa M; Alobid I; Mullol J; Pujols L; Roca-Ferrer J; Picado C
J Allergy Clin Immunol; 2016 Jan; 137(1):99-107.e7. PubMed ID: 26560040
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Lewis E; Gakpo D; Hacker J; Sohail A; Taliaferro F; Berreondo Giron E; Asare C; Vukovic M; Bensko JC; Dwyer DF; Shalek AK; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD).
Priyadharshini VS; Jiménez-Chobillon MA; de Graaf J; Porras Gutiérrez de Velasco R; Gratziou C; Ramírez-Jiménez F; Teran LM
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439758
[TBL] [Abstract][Full Text] [Related]
14. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Pezato R; Świerczyńska-Krępa M; Niżankowska-Mogilnicka E; Holtappels G; De Ruyck N; Sanak M; Derycke L; Van Crombruggen K; Bachert C; Pérez-Novo CA
Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
Cahill KN; Bensko JC; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2015 Jan; 135(1):245-52. PubMed ID: 25218285
[TBL] [Abstract][Full Text] [Related]
16. A trial of type 12 purinergic (P2Y
Laidlaw TM; Cahill KN; Cardet JC; Murphy K; Cui J; Dioneda B; Kothari P; Raby BA; Israel E; Boyce JA
J Allergy Clin Immunol; 2019 Jan; 143(1):316-324.e7. PubMed ID: 29890239
[TBL] [Abstract][Full Text] [Related]
17. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Taniguchi M; Mitsui C; Hayashi H; Ono E; Kajiwara K; Mita H; Watai K; Kamide Y; Fukutomi Y; Sekiya K; Higashi N
Allergol Int; 2019 Jul; 68(3):289-295. PubMed ID: 31235242
[TBL] [Abstract][Full Text] [Related]
18. Group 2 innate lymphoid cells in nasal polyposis.
Stevens WW; Kato A
Ann Allergy Asthma Immunol; 2021 Feb; 126(2):110-117. PubMed ID: 32781240
[TBL] [Abstract][Full Text] [Related]
19. Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?
Klimek L; Dollner R; Pfaar O; Mullol J
Curr Allergy Asthma Rep; 2014 Jun; 14(6):441. PubMed ID: 24682773
[TBL] [Abstract][Full Text] [Related]
20. Steroids Inhibit Eosinophil Accumulation and Downregulate Hematopoietic Chemotaxic Prostaglandin D
Suzuki N; Ko-Mitamura EP; Inui T; Terada T; Dejima K; Nagata N; Urade Y; Kawata R
Ear Nose Throat J; 2021 Sep; 100(5_suppl):738S-745S. PubMed ID: 32077309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
